Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
J.P. Morgan

Device Week, 21 January 2022 – J.P. Morgan Health Care Conference Highlights; Spotlight PneumoWave

On this week’s podcast, Medtech Insight's Reed Miller, Marion Webb and Barnaby Pickering provide a recap of our J.P. Morgan Health Care conference coverage including Abbott, Dexcom, Zimmer Biomet and Nuvasive and spotlight Scottish company PneumoWave. 

Device Week Business Strategies

Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow

Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.

Finance Watch

Pipeline Watch: Six Japanese Approvals Plus Eight Phase III Trial Results

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Zymeworks Cuts C-Suite In Half At Crunch Time For Pipeline

New Zymeworks CEO Ken Galbraith is laying off at least 25% of the company's staff, including 50% of the senior management team, as the firm looks to advance pivotal trials of its HER2-targeted bispecific antibody zanidatamab.

Business Strategies Cancer

Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans

GSK now looks free to pursue its ‘Plan A’ for the consumer division, but activist investors may push for a new bidder to be found.

Companies Commercial

AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.

Clinical Trials Companies

Executives On The Move: Changes At Exicure, H-Cyte Inc. And More

Recent executive changes in the industry include the appointment of a new Chief Medical Officer at Caribou Biosciences and promotions at Exicure. Meanwhile, H-Cyte Inc., among other companies, has chosen new independent directors.

Executive Changes Leadership

Entry Reminder For Pharma Intelligence Awards Japan

The 4 February entry deadline is looming for the inaugural Informa Pharma Intelligence Awards Japan, which will be held in Tokyo on 12 May 2022 to recognize and reward the very best innovations and achievements in pharma and biotech, highlighting Japan's integral role in the global healthcare market.

Japan Commercial

Keytruda Adds To Women’s Oncology Lead With Endometrial Cancer Data

Published data showed Merck’s PD-1 inhibitor combined with Eisai’s Lenvima improved survival in the all-comer population of previously treated endometrial carcinoma.

Cancer ImmunoOncology

Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)

Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.

Sales & Earnings Launches

Big Year For UCB As Bimzelx Awaits US Green Light

The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.

Immune Disorders Approvals
See All
UsernamePublicRestriction

Register